QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:VRCA

Verrica Pharmaceuticals Stock Forecast, Price & News

$9.12
-0.03 (-0.33 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.84
Now: $9.12
$9.30
50-Day Range
$7.41
MA: $8.49
$9.63
52-Week Range
$6.02
Now: $9.12
$17.60
Volume79,851 shs
Average Volume112,251 shs
Market Capitalization$235.90 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300
Employees17

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-28,210,000.00

Miscellaneous

Market Cap$235.90 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable
$9.12
-0.03 (-0.33 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

How has Verrica Pharmaceuticals' stock price been impacted by Coronavirus?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRCA stock has decreased by 13.3% and is now trading at $9.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Verrica Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Verrica Pharmaceuticals?

Wall Street analysts have given Verrica Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verrica Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Verrica Pharmaceuticals
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its quarterly earnings data on Monday, November, 9th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.01.
View Verrica Pharmaceuticals' earnings history
.

What price target have analysts set for VRCA?

4 brokers have issued 1-year price objectives for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals
.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 1,860,000 shares, a decrease of 21.2% from the October 15th total of 2,360,000 shares. Based on an average daily volume of 170,900 shares, the days-to-cover ratio is currently 10.9 days. Currently, 14.7% of the shares of the stock are sold short.
View Verrica Pharmaceuticals' Short Interest
.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 55, Pay $666.19k)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 53, Pay $342.85k)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 56, Pay $528.11k)
  • Dr. Gary Goldenberg M.D., Chief Medical Officer (Age 43, Pay $55k)
  • Mr. Christopher G. Hayes, Chief Legal Officer, Sec. & Gen. Counsel (Age 56)
  • Mr. Eugene Scavola, Exec. VP of Technical Operations
  • Dr. Bradley J. Catalone MBA, Ph.D., Head of Drug Devel.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.65%), Kornitzer Capital Management Inc. KS (2.61%), State Street Corp (0.90%), FinTrust Capital Advisors LLC (0.04%), Morgan Stanley (0.02%) and New York State Common Retirement Fund (0.02%). Company insiders that own Verrica Pharmaceuticals stock include A Brian Davis, Craig Ballaron, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals
.

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., New York State Common Retirement Fund, State Street Corp, and Morgan Stanley.
View insider buying and selling activity for Verrica Pharmaceuticals
.

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was purchased by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, FinTrust Capital Advisors LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include A Brian Davis, Craig Ballaron, Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals
.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $9.12.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $235.90 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 17 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.